<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03933215</url>
  </required_header>
  <id_info>
    <org_study_id>MS700568_0078</org_study_id>
    <nct_id>NCT03933215</nct_id>
  </id_info>
  <brief_title>A Study of Suboptimally Controlled Participants Previously Taking Injectable Disease-modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)</brief_title>
  <acronym>CLICK-MS</acronym>
  <official_title>Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Injectable Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) (CLICK-MS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness and safety of cladribine tablets in participants with RMS
      including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive
      multiple sclerosis (aSPMS),who transition to cladribine tablets after suboptimal response to
      any injectable DMD approved in the United States (US) for RMS in a real-world setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Anticipated">November 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Relapse Rate (ARR) (Prospective Assessment)</measure>
    <time_frame>Baseline (Month 0) up to 24 Months</time_frame>
    <description>For this study, a relapse will be defined as per routine clinical practice as determined by the investigator. As a guide, relapse may be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. ARR up to 24 months of treatment with cladribine tablets, after baseline (prospectively collected data) will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 14-Item Treatment Satisfaction Questionnaire for Medication (TSQM-14) Total Score at Month 6, 12 and 24</measure>
    <time_frame>Baseline (Month 0), Month 6, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short Form Health Survey (SF-36) Total Score at Month 6, 12 and 24</measure>
    <time_frame>Baseline (Month 0), Month 6, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Fatigue Impact Scale - 5-item version (MFIS-5) Total Score at Month 6, 12 and 24</measure>
    <time_frame>Baseline (Month 0), Month 6, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 7-Item Beck-Depression Inventory-Fast Screen (BDI-FS) Total Score at Month 6, 12 and 24</measure>
    <time_frame>Baseline (Month 0), Month 6, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 6-Item Work Productivity Activity Impairment - Multiple Sclerosis (WPAI-MS) Total Score at Month 6, 12 and 24</measure>
    <time_frame>Baseline (Month 0), Month 6, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Determined Disease Steps (PDDS) Scale Total Score at Month 6, 12 and 24</measure>
    <time_frame>Baseline (Month 0), Month 6, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adherence to Treatment as Assessed by Modified Versions of the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)</measure>
    <time_frame>Baseline (Month 0) and at the end of Months 1, 2, 13 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Relapse (Prospective Assessment)</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>For this study, a relapse will be defined as per routine clinical practice as determined by the investigator. As a guide, relapse may be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. Percentage of participants with relapse up to 24 months of treatment with cladribine tablets, after baseline (prospectively collected data) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Relapse Associated With Hospitalization, Diagnosis or Reason for Hospitalization</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>For this study, a relapse will be defined as per routine clinical practice as determined by the investigator. As a guide, relapse may be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. Percentage of participants with relapse associated with hospitalization, diagnosis or reason for hospitalization will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Relapse Associated With Glucocorticoid Use</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>For this study, a relapse will be defined as per routine clinical practice as determined by the investigator. As a guide, relapse may be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. Percentage of participants with relapse associated with glucocorticoid use up to 24 months of treatment with cladribine tablets, after baseline (prospectively collected data) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Pattern as Evaluated by Number of Participants With Previous Treatment for Multiple Sclerosis (MS)</measure>
    <time_frame>At Baseline (Month 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinue Cladribine Tablets</measure>
    <time_frame>Baseline (Month 0) up to 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Reason for Discontinuation of Cladribine Tablets</measure>
    <time_frame>Baseline (Month 0) up to 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elapsed Time to Discontinuation After First Dose of Cladribine Tablets</measure>
    <time_frame>Baseline (Month 0) up to 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Doses Received by Participants as per United States Prescribing Information</measure>
    <time_frame>Baseline (Month 0) up to 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Planned Doses Received by Participants as per United States Prescribing Information</measure>
    <time_frame>Baseline (Month 0) up to 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Subsequent Treatment Chosen Following Discontinuation of Cladribine Tablets</measure>
    <time_frame>Baseline (Month 0) up to 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Assessed of Concomitant Multiple Sclerosis Medications Used During Study Period</measure>
    <time_frame>Baseline (Month 0) up to 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Relapse Rate (ARR) (Retrospective Assessment)</measure>
    <time_frame>Up to 24 Months prior Baseline (Month 0)</time_frame>
    <description>For this study, a relapse will be defined as per routine clinical practice as determined by the investigator. As a guide, relapse may be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. ARR up to 24 months prior to baseline (retrospectively collected data) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs), Adverse Drug Reactions (ADRs), Adverse Events of Special Interest (AESIs) and Special Situations</measure>
    <time_frame>Baseline (Month 0) up to 24 months</time_frame>
    <description>A serious adverse event (SAE) is an adverse event (AE) that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or is otherwise considered medically important. An ADR is a response to a medicinal product which is noxious and unintended. An AESI is an AE of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor can be appropriate.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cladribine Tablets</arm_group_label>
    <description>No intervention will be administered as a part of this study. Participants who had decided prior to enrollment to transition from any injectable DMD to treatment with cladribine tablets under routine clinical care and who meet all eligibility criteria will receive an initial treatment course with cladribine tablets in Year 1 and are planned to receive a second course in Year 2, as per the approved United States Prescribing Information (USPI). Data sources for this study will include data extracts from participants' medical records performed by site personnel as well as questionnaires directly filled out by participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine Tablets</intervention_name>
    <description>No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.</description>
    <arm_group_label>Cladribine Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Multiple Sclerosis and experienced suboptimal response (lack of
        effectiveness, intolerability, poor adherence) to prior treatment with an injectable DMD.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participants greater than or equal to (&gt;=)18 years

          -  Signed informed consent

          -  Have diagnosis of RMS including RRMS and aSPMS and satisfy the approved indication for
             cladribine tablets as per United States Prescribing Information (USPI)

          -  Have time since diagnosis of RMS of at least 12 months

          -  Had received their last previous injectable disease-modifying drug (DMD) for at least
             3 months

          -  Have decided to initiate treatment with cladribine tablets during routine clinical
             care

          -  Meet criteria as per the approved USPI

          -  Have access to a valid e-mail address

          -  In the opinion of the Investigator, experienced suboptimal response (lack of
             effectiveness, intolerability, poor adherence) to injectable DMD treatment

        Exclusion Criteria:

          -  Have been previously treated with cladribine in any dosing form

          -  Transitioning from previous injectable DMD solely for administrative reasons such as
             relocation

          -  Have comorbid conditions that preclude participation

          -  Have any clinical condition or medical history noted as contraindication on USPI

          -  Are currently participating in an interventional clinical trial

          -  Pregnant or breastfeeding women, women who plan to become pregnant or men whose
             partner plans to become pregnant during the cladribine treatment period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono Inc., the biopharmaceutical division of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>eMediUSA@emdserono.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36693</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>lmbarganier2@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Barganier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regina Berkovich MD PhD INC</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>reginaberkovichmd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Regina Berkovich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mountain Neurological Research Center</name>
      <address>
        <city>Basalt</city>
        <state>Colorado</state>
        <zip>81621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>allen@roaringforkneurology.com</email>
    </contact>
    <investigator>
      <last_name>Alison Brooke Allen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Springs Neurological Associates, PC - Neurology</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>aeadala@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aparna Komatineni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCA Research Institute</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>abneurocare@qwestoffice.net</email>
    </contact>
    <investigator>
      <last_name>Allen C Bowling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Neurosciences Research</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>amiravalle@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Augusto A Miravalle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>neetagarg@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Neeta Garg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suncoast Neuroscience and Associates, Inc.</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>abvmd@aol.com</email>
    </contact>
    <investigator>
      <last_name>Alberto B Vasquez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Roskamp Institute - Clinical Trials Division</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>akeegan@roskampinstitute.org</email>
    </contact>
    <investigator>
      <last_name>Andrew P Keegan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Axiom Clinical Research of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mcascione.axiom@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mark C Cascione Cascione</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>droberts@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Derrick S Robertson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Education &amp; Research</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>reuben.valenzuela@hshs.org</email>
    </contact>
    <investigator>
      <last_name>Reuben M Valenzuela</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Neurological Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>agupta@fwnc.com</email>
    </contact>
    <investigator>
      <last_name>Ajay S Gupta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>College Park Family Care Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jeffrey.kaplan@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey M Kaplan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>james.winkley@bhsi.com</email>
    </contact>
    <investigator>
      <last_name>James M Winkley Winkley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky - Department of Neurology</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>javasarala@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Jagannadha Avasarala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuro Institute of New England P.C.</name>
      <address>
        <city>Foxboro</city>
        <state>Massachusetts</state>
        <zip>02035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>snapoli@myneurodr.com</email>
    </contact>
    <investigator>
      <last_name>Salvatore Napoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center, Inc.</name>
      <address>
        <city>Jamaica Plain</city>
        <state>Massachusetts</state>
        <zip>02130-2075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jsloane@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jacob A Sloane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Elliot Lewis Center for Multiple Sclerosis Care, LLC</name>
      <address>
        <city>Wellesley</city>
        <state>Massachusetts</state>
        <zip>02481</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joshua Katz, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMASS - Neurology</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>andrew.bouley@umassmemorial.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Bouley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mcerghe1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Mirela Cerghet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare</name>
      <address>
        <city>Owosso</city>
        <state>Michigan</state>
        <zip>48867</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>rob@paceneuro.com</email>
    </contact>
    <investigator>
      <last_name>Robert J Pace</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Steven Schechter's Office</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>steven.schechter@dcrc.us</email>
    </contact>
    <investigator>
      <last_name>Steven H Schechter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Clinic of Neurology - Neurology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jessica.stulc@mpls-clinic.com</email>
    </contact>
    <investigator>
      <last_name>Jessica L Stulc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Research - Mercy Hospital St. Louis Research Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>amy.rauchway@mercy.net</email>
    </contact>
    <investigator>
      <last_name>Amy C Rauchway</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Center of Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sdixit@interspond.com</email>
    </contact>
    <investigator>
      <last_name>Shanker N Dixit</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Brooklyn - Brooklyn</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>nada.abou-fayssal@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Nada G Abou-Fayssal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Associates of Long Island, P.C.</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>tracydeangelis73@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Teresa DeAngelis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Trustee of Columbia University in the City of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>rs3648@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Rebecca Farber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guilford Neurologic Associates</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>richard.sater@conehealth.com</email>
    </contact>
    <investigator>
      <last_name>Richard Sater</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insight Neuroscience LLC</name>
      <address>
        <city>Bellevue</city>
        <state>Ohio</state>
        <zip>44811</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>bbauer@advneuroassoc.com</email>
    </contact>
    <investigator>
      <last_name>Brendan W Bauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riverhills Neuroscience</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mbowman@riverhillsneuro.com</email>
    </contact>
    <investigator>
      <last_name>Michelle Bowman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dayton Center for Neurological Disorders</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kmankowski@dcndinc.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth A Mankowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toledo - PARENT</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614-2598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>talal.derani@utoledo.edu</email>
    </contact>
    <investigator>
      <last_name>Talal Derani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MDH Research, LLC</name>
      <address>
        <city>Westerville</city>
        <state>Ohio</state>
        <zip>43081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>dhuang@mdhresearch.com</email>
    </contact>
    <investigator>
      <last_name>Deren Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Neurological Specialties</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kyle.smoot@providence.org</email>
    </contact>
    <investigator>
      <last_name>Kyle E Smoot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wills Eye Institute - Ocular Oncology Service - Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>rcs220@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Robert C Sergott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Texas Neurology Consultants</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ctnc.research@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Edward J Fox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>annofb@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ann D Bass</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care, Inc. - Hematology/Oncology Unit</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>chantal.roy-hewitson@vtmednet.org</email>
    </contact>
    <investigator>
      <last_name>Chantal Roy-Hewitson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Neurology Services - Dr. Simon Fishman's Office</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sfishman@integratedneurologyservices.com</email>
    </contact>
    <investigator>
      <last_name>Simon Fishman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blacksburg Neurology, PC</name>
      <address>
        <city>Christiansburg</city>
        <state>Virginia</state>
        <zip>24073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cramerj01@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jill Cramer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Associates</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>alan.schulman@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Alan E Schulman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VCU Medical Center - Pediatric Neurology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>wlfelton@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Warren L Felton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Ambulatory Care Center</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mbkuczma@sentara.com</email>
    </contact>
    <investigator>
      <last_name>Michelle B Kuczma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MS Center of Evergreen</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trbrown@evergreenhealth.com</email>
    </contact>
    <investigator>
      <last_name>Theodore R Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuroscience Group of Northeast Wisconsin</name>
      <address>
        <city>Neenah</city>
        <state>Wisconsin</state>
        <zip>54956</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Susan Hibba, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS700568_0078</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Cladribine Tablets</keyword>
  <keyword>Observational</keyword>
  <keyword>Mavenclad</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

